Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing family tumors

• Published in: Pediatric blood & cancer Vol. 49; no. 2; pp. 196 - 198
• Main Authors: Burke, Michael J., Walterhouse, David O., Jacobsohn, David A., Duerst, Reggie E., Kletzel, Morris
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.08.2007
• Subjects: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bone Neoplasms - drug therapy; Bone Neoplasms - secondary; Bone Neoplasms - surgery; Bone Neoplasms - therapy; Child; Combined Modality Therapy; Cyclophosphamide - administration & dosage; Doxorubicin - administration & dosage; Drug Administration Schedule; Etoposide - administration & dosage; Ewing sarcoma; Feasibility Studies; Female; high-dose chemotherapy; Humans; Ifosfamide - administration & dosage; Lung Neoplasms - drug therapy; Lung Neoplasms - secondary; Lung Neoplasms - surgery; Lung Neoplasms - therapy; Male; Mesna - administration & dosage; Neoadjuvant Therapy; Neuroectodermal Tumors, Primitive - drug therapy; Neuroectodermal Tumors, Primitive - surgery; Pelvic Bones - surgery; Peripheral Blood Stem Cell Transplantation; PNET; Remission Induction; Risk; Sarcoma, Ewing - drug therapy; Sarcoma, Ewing - radiotherapy; Sarcoma, Ewing - secondary; Sarcoma, Ewing - surgery; Sarcoma, Ewing - therapy; Scapula - surgery; tandem autologous stem cell transplantation; Transplantation Conditioning - methods; Transplantation, Autologous; Treatment Outcome; Vincristine - administration & dosage
• ISSN: 1545-5009; 1545-5017
• DOI: 10.1002/pbc.21182

The role of tandem high‐dose chemotherapy (HDC) with autologous peripheral hematopoietic progenitor cell rescue (APHPCR) in patients with Ewing Family Tumors (EFT) is controversial. We initiated treatment for eight consecutive patients with high‐risk EFT with HDC and APHPCR from 1992 to 2003. There were no treatment related deaths. Four patients remain in complete remission, including three who did not undergo local therapy to bone at either the primary or metastatic sites. Our experience has shown that treatment of EFT patients with tandem HDC with APHPCR may benefit a subgroup of high‐risk patients in whom optimal local therapy is not possible. Pediatr Blood Cancer 2007;49:196–198. © 2007 Wiley‐Liss, Inc.